Eccogene (shanghai) Co., Ltd.

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Eccogene Inc.

Zaifang Ren

Xuefeng Sun

Qing Xu

Jingye Zhou

Jian Li

Shuhui Chen

Jie Li

Zhifei Fu

Miaorong Luo

Dongjie Hu

The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.

Substituted imidazoles as GLP-1 receptor agonists

The application relates to a compound of Formula (I′) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

SSAO inhibitors and use thereof

The application relates to a compound of Formula (I') or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I&#x2032;) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

Disclosed are a compound as shown in formula (I), and an isomer thereof or a pharmaceutically acceptable salt thereof, and involved is the use thereof in the preparation of drugs for treating FGFR-associated diseases. 

Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor

Growing community of inventors

Shanghai, China

Zaifang Ren